Evidence map›Paper›PMID 31357921›Full record

ArticlePsychiatric services (Washington, D.C.)2019

Lung Cancer Screening Eligibility, Risk Perceptions, and Clinician Delivery of Tobacco Cessation Among Patients With Schizophrenia.

Kelly E Irwin, Eleanor B Steffens, YooJin Yoon, Efren J Flores, Helen P Knight, William F Pirl, Oliver Freudenreich, David C Henderson, Elyse R Park

Registry-linked trialAbstract read
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05784922 (Health Opportunities and Promoters of Equitable Screening for Lung Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05784922 recruitingnot on this mapstarted 2023, after this paper: background citation

Health Opportunities and Promoters of Equitable Screening for Lung Cancer (HOPES for Lung Cancer)

TypeobservationalSponsorMassachusetts General HospitalRan2023 to 2028Enrolled2,000ConditionsLung Cancer, Smoking Behaviors, DiagnosisArmsEducational Lung Cancer Screening (LCS) Video
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. The Risk and The Course of Cancer Among People with Severe Mental Illness.Clinical practice and epidemiology in mental health : CP & EMH · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kelly E IrwinCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
Eleanor B SteffensCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
YooJin YoonCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
Efren J FloresCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
Helen P KnightCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
William F PirlCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
Oliver FreudenreichCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
David C HendersonCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).
Elyse R ParkCenter for Psychiatric Oncology and Behavioral Sciences, Massachusetts General Hospital Cancer Center, Boston (Irwin, Yoon); Schizophrenia Clinical and Research Program (Irwin, Freudenreich), Mongan Institute Health Policy Center (Steffens, Park), Tobacco Research and Treatment Center (Park), and Department of Radiology (Flores), Massachusetts General Hospital, Boston; Erich Lindemann Mental Health Center, Boston (Freudenreich); Department of Medicine, Brigham and Women's Hospital, Boston (Knight); Dana-Farber Cancer Institute, Boston (Pirl); Department of Psychiatry, Boston Medical Center and Boston University, Boston (Henderson).

Funding

Reducing Disparities in Underserved Patients with Cancer and Serious Mental IllnessK08CA230185 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI IRWIN, KELLY EDWARDS · 2018 to 2022
$1.1M
NCI NIH HHS K08 CA230185
6 · The paper itself

Abstract

objectiveIndividuals with schizophrenia experience increased lung cancer mortality and decreased access to cancer screening and tobacco cessation treatment. To promote screening among individuals with schizophrenia, it is necessary to investigate the proportion who meet screening criteria and examine smoking behaviors, cancer risk perception, and receipt of tobacco cessation interventions from psychiatry and primary care.

methodsThe authors performed a cross-sectional survey and medical record review with 112 adults with schizophrenia treated with clozapine in a community mental health clinic (CMHC).

resultsAmong older participants (ages 55-77 years) with schizophrenia, 34% met the criteria for lung screening on the basis of smoking history (heavy current or former smokers), and more than half believed they had a low risk of developing lung cancer. Of all participants, 88% had visited their primary care provider (PCP) in the past year; PCPs represented 35 different practices. Only one in three current smokers reported that their PCP or psychiatrist assisted them in obtaining medications for tobacco cessation.

conclusionsGiven smoking history, many older adults with schizophrenia have potential to benefit from lung screening, yet most older participants underestimated their lung cancer risk. Although participants regularly accessed care, PCP and psychiatric visits may be missed opportunities to engage patients with schizophrenia in tobacco cessation and decrease preventable premature mortality. Embedding interventions in a CMHC, a centralized access point of care delivery for patients with schizophrenia, may have unique potential to increase uptake of cancer screening and tobacco cessation interventions.

Indexed as

Early Detection of CancerAdultCross-Sectional StudiesEligibility DeterminationFemaleHumansLung NeoplasmsMaleMiddle AgedPractice Guidelines as TopicPrimary Health CareRisk AssessmentSchizophreniaSmokingSmoking CessationTobacco Use Disorder

Identifiers

PMID31357921
PMCPMC8386131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.